day 1 agenda


7th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
on Sep 07-08, 2026 at Paris, France
Day -1(Sep 07, 2026)
Tentative Program
09:00-09:30 KeynoteTalk: Genetic Therapies for APOE4-Associated Alzheimer’s Diseases
Ronald Crystal, Weill Cornell Medicine, USA
09:30-10:00 KeynoteTalk: GABA-A receptor modulating steroids enhance dementia, but antagonists inhibit inflammation and improve memory
Torbjörn Bäckström, Umeå University, Sweden
10:00-10:30 KeynoteTalk: Glomerular (mesangial) amyloidogenesis in AL (light chain-associated) amyloidosis: Translational studies with implications for further treatment modalities. Similarities with amyloid formation in Alzheimer disease
Guillermo A. Herrera, University of South Alabama, USA
Group Photo & Refreshment Break (10:30-10:50)
Technical session-I
10:50-11:10 Obtaining personalized predictions from a randomized controlled trial on Alzheimer’s disease
Dennis Shen, University of Southern California, USA
11:10-11:30 The Traumatic brain injury and the risk of dementia
Wendy Lin, University of British Columbia, Canada
11:30-11:50 Slot Available
11:50-12:10 Nonhuman Primate Models of Alzheimer’s Disease And Parkinson’sDisease Co-pathologies
Jeffrey H. Kordower, Arizona State University, USA
12:10-12:30 Relationships among tau, amyloid, neuroinflammation, NMDA receptors and cognitive performance are strongly modulated by sex
Anat Biegon, University of Uppsala, Sweden
12:30-12:50 Intermittent hypoxia training attenuates brain atrophy in elderly adultswith mild cognitive impairment
Xiangrong Shi, University of North Texas Health Science Centre, USA
12:50-13:10 Slot Available
Lunch Break @ Restaurant (13:10-14:00)
Technical session-II
14:00-14:20 Arterial Tortuosity as a Marker of Cerebrovascular Aging and Dementia Risk
Yulin Ge, NYU Grossman School of Medicine, USA
14:20-14:40 The Enigma of Brain Iron: From Brain Iron Overload to Functional Iron Deficiency in Neurodegenerative Diseases
Levi Sonia, University Vita-Salute San Raffaele , Italy
14:40-15:00 Gut virome signatures and bacteriophage–bacterial interactions in amyloid-positive Alzheimer’s disease
Mahin Ghorbani, Karolinska Institutet, Sweden
15:00-15:20 Slot Available
15:20-15:40 Stepwise identification of prodromal dementia: testing a practical model for primary care
Boaz Levy, University of Massachusetts Boston, USA
15:40-16:00 Cortical neuron dysfunction in AD brain at early-stage without beta-amyloid aggregation
Xiu-Ti Hu, Rush University Medical Center, USA
16:00-16:20 Digital Twins in Clinical Trials for Alzheimer’s Disease
Irfan Chaudhuri, Harvard University, USA
16:20-16:40 Slot Available
Refreshment Break(16:40-16:50)
Note: This is a Tentative program, subjects and timings will changes.
Day-1 Concludes

day 2 agenda

Scientific Program
7th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA 
Sep 07 - 08, 2026 at Paris, France (Hybrid Event)
Day -2 (September 08, 2026)
Keynote Forum | 09:30-11:00
11:00-11:20 | Group Photo & Refreshment Break
Technical Session I | 11:20-13:00
13:00-14:00 | Lunch Break
Technical Session II | 14:00-16:00
16:00-16:20 | Refreshment Break
Technical Session III | 16:20-17:30
Panel Discussion & Closing Ceremony

posters agenda

7th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
on Sep 07-08, 2026 at Paris, France
Day -1(Sep 07, 2026)- Virtual Program
Tentative Program
10:00 – 10:20 6-microRNA panel predicts amyloid-b status in cognitively normal older adults
Joanna M. Williams, University of Otago, NewZealand
10:20 – 10:40 Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a
Kazumi Saikusa, National Metrology Institute of Japan (NMIJ), Japan
10:40 – 11:00 Slot Available
11:00 – 11:20 Huntingtin’s N17 region: Post-translational modifications as modulators of protein self-association and membrane interaction
Mariana Gallo, University of Parma, Italy
11:20-11:50 Keynote Talk: NAP, the investigational drug davunetide, from laboratory discovery to sex-specific cognitive protection in clinical trials
Illana Gozes, Tel Aviv University, Israel
11:50-12:10 Selective manipulation of aging as a novel treatment for neurodegenerative disorders
Ehud Cohen, The Hebrew University School of Medicine, Israel
12:10-12:30 Slot Available
12:30-12:50 Early Linguistic Indicators and Language-Focused Therapies in Alzheimer’s Disease
Erika Smeriglio, University of Messina, Italy
12:50 – 13:10 Slot Available
13:10 – 13:30 Correction of the APP London (V717I) mutation using
an optimized prime editing system.
Jacques P. Tremblay, Université Laval, Canada
13:30 – 13:50 Methionine-sulfoxide based active immunization against Alzheimer’s disease
Jackob Moskovitz, University of Kansas, USA
13:50-14:20 Keynote Talk: Elovanoids: linking nutrition to neuroprotection
Nicolas G. Bazan, Neuroscience Center of Excellence, USA
14:20 – 14:40  Spiritual Fitness: The New Dimension In Alzheimer’s Disease Prevention
Eve Adler, Alzheimer's Research and Prevention Foundation, USA
14:40 – 15:00 The importance of social relationships in place in Alzheimer’s Disease
George Rook, a person living with dementia and co-researcher on several projects, USA
15:00 – 15:30 Slot Available
15:30 – 15:50  Establishing two-tier cutoffs for ptau217/A42 ratio in plasma for detection of Alzheimers disease pathology
Leslie M Shaw, University of Pennsylvania, USA
15:50 – 16:10  Air pollution risk of Alzheimer in a mouse model of amyloidogenesis
 is attenuated by modulation of gamma-secretase
Caleb E Finch, University of Southern California, USA
Day-1 Concludes
   
Day -2(Sep 08, 2026)- Virtual Program
Tentative Program
10:00 – 10:20 Cultural Perspectives on Virtual delivery of Cognitive Stimulation Therapy for M?ori with Dementia (vCST-M?ori)
Tai Kake, University of Auckland, NewZealand
10:20 – 10:40 Revitalizing Mitochondria against Alzheimer’s disease: The Synergistic Effects of a Nutraceutical Combination with urolithin A
Dona Pamoda W. Jayatunga, University of Sri Jayewardenepura, Sri Lanka
10:40 – 11:00 Slot Available
11:00 – 11:20 Slot Available
11:20-11:50 Keynote Talk: Restoring neuronal function by restoring the septin cytoskeleton
Gerard Griffioen, remynd, Belgium
11:50-12:10 Targeting the GSK3β/Nav1.6 protein–protein interaction offers a promising new therapeutic approach for early-stage Alzheimer’s disease
Fernanda Laezza, University of Texas Medical Branch, USA
12:10-12:30  From amyloid plaques to tau neurofibrillary tangles:
Connecting the dots in Alzheimer’s disease through GPC4
Brandon B. Holmes, University of California, USA
12:30-12:50  Non-catalyzed covalent dimerization of amyloid b and implications for Alzheimer’s disease
Suren A. Tatulian, University of Central Florida, USA
12:50 – 13:10 Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide
Ken Teter, University of Central Florida, USA
13:10 – 13:30 Slot Available
13:30 – 13:50 Alzheimer’s Is Dynamic – Our Language Has Not Kept Pace: Redefining Diagnosis Through Precision and Human-Centered Staging
Lauren P. Brown, The Alzheimer's Experience, USA
13:50-14:20 Keynote Talk: Systems Thinking
Michael Fossel,  Michigan State University, USA
14:20 – 14:40  Identification of novel shared antibodies and infectious disease associations in Alzheimer’s disease
Mark Hicar, University at Buffalo, USA
14:40 – 15:00 Slot Available
15:00 – 15:30 Slot Available
15:30 – 15:50 Slot Available
15:50 – 16:10 Slot Available
Day-2 Concludes
This is a tentative program. The schedule and session topics are subject to change

Download